Business Context and Reporting Period
Company: Acasti Pharma Inc. (Note: Request metadata listed "Grace Therapeutics," but the filing text identifies the registrant as Acasti Pharma Inc.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended February 28, 2015
Business Overview: Acasti is an emerging biopharmaceutical company focused on developing krill oil-based omega-3 phospholipid therapies. Its primary prescription drug candidate, CaPre®, is in clinical development for the treatment of hypertriglyceridemia. Its only commercialized product is ONEMIA®, a medical food for dietary management of lipid profiles. The company is a subsidiary of Neptune Technologies & Bioressources Inc.
Key Financial Metrics
| Metric (CAD) | Fiscal 2015 | Fiscal 2014 | Fiscal 2013 |
|---|---|---|---|
| Revenue from Sales | $270,615 | $500,875 | $724,196 |
| Gross Profit | $35,524 | $209,022 | $317,825 |
| Net Loss | $(1,654,724) | $(11,611,649) | $(6,892,360) |
| Loss Per Share (Basic/Diluted) | $(0.02) | $(0.14) | $(0.09) |
| Total Assets | $37,208,105 | $45,631,803 | $12,170,048 |
| Cash and Short-Term Investments | $18,381,900 | $23,701,441 | N/A |
| Total Liabilities | $3,979,786 | $12,352,303 | $2,446,372 |
| Shareholders' Equity | $33,228,319 | $33,279,500 | $9,723,676 |
Note: All figures are in Canadian Dollars (CAD) unless otherwise specified. The significant reduction in Net Loss for 2015 compared to 2014 was primarily driven by a non-cash gain of approximately $8.8 million related to the change in fair value of derivative warrant liabilities.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 46% to $271,000 from $501,000 in the prior year. This decline is attributed to the company's reliance on a limited number of distributors and variability in sales of ONEMIA®.
- Improved Net Loss: Net loss improved significantly to $1.65 million from $11.61 million. This improvement is largely due to a $8.8 million unrealized gain on derivative warrant liabilities (due to a decline in stock price) and foreign exchange gains, offset by increased amortization expenses related to a license prepayment asset.
- Operating Expenses: Research and development expenses increased to $6.52 million (net of tax credits) from $4.30 million, driven by higher contract expenses and professional fees for clinical trials. General and administrative expenses decreased slightly to $5.91 million from $6.71 million.
- Liquidity: Cash and short-term investments decreased to approximately $18.4 million from $23.7 million, primarily due to the maturity of investments and operating cash outflows.
Guidance, Outlook, and Risks
Outlook and Strategy
- Clinical Development: Acasti has completed Phase II trials (COLT and TRIFECTA) for CaPre®, reporting positive results in reducing triglycerides. The company is currently corresponding with the FDA to determine next steps, including the design of a pivotal Phase III clinical trial for severe hypertriglyceridemia.
- Commercialization: The company plans to seek commercial partners for CaPre® upon approval. It continues to generate modest revenue from ONEMIA® to support R&D.
- Capital Needs: Management expects to incur substantial losses for the foreseeable future. While current cash reserves are deemed sufficient for the next 12 months, the company will likely require additional capital to fund Phase III trials and regulatory filings.
Key Risks and Contingencies
- Regulatory Approval: There is no assurance that CaPre® will receive FDA approval. The company has no approved prescription drugs and depends entirely on CaPre® for future revenue.
- NASDAQ Compliance: The company received notification from NASDAQ regarding failure to maintain a minimum bid price of $1.00 per share. It was granted an extension until November 2, 2015, to regain compliance, potentially through a share consolidation.
- Legal Proceedings: Former CEO Henri Harland filed a lawsuit seeking approximately $8.5 million in damages and equity. The company contests the claim, alleging the contract is void or that dismissal for cause was justified. No provision has been recorded as the outcome is uncertain.
- Supply Chain: The company relies on third parties (including parent company Neptune) for the supply of raw krill oil and manufacturing of CaPre®.
Investor Verification Checklist
- Cash Runway: Verify if the $18.4 million in cash is sufficient to fund the planned Phase III trial and NDA filing without immediate dilution or debt financing.
- NASDAQ Status: Monitor the company's ability to regain compliance with the $1.00 minimum bid price rule by November 2015 to avoid delisting.
- Legal Exposure: Track the status of the Henri Harland lawsuit, as a negative outcome could result in significant financial liability or equity dilution.
- Derivative Liability Volatility: Understand that reported net income/loss is heavily influenced by non-cash fair value adjustments of warrant liabilities, which fluctuate with the stock price.
- Revenue Concentration: Assess the risk associated with revenue concentration, as over 83% of ONEMIA® sales in 2015 came from a single distribution partner.